Join to View Full Profile
520 East 70th StreetStarr Pavilion, 3rd FloorNew York, NY 10021
Phone+1 646-962-7950
Dr. Hsu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- I am a board certified hematologist specializing stem cell transplant and cellular therapy. I completed my hematology/oncology fellowship at Hospital of University of Pennsylvania.
Education & Training
Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Internal Medicine, 2008
State University of New York Downstate Medical Center College of MedicineClass of 2007
Certifications & Licensure
NY State Medical License 2008 - 2027
PA State Medical License 2008 - 2016
NJ State Medical License 2006 - 2010
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016
Publications & Presentations
PubMed
- 2 citationsFive-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma.Richard T Maziarz, Michael R Bishop, Constantine S Tam, Peter Borchmann, Nina Worel
Journal of Clinical Oncology. 2026-01-10 - Allogeneic Hematopoietic Stem Cell Transplantation After Solid Organ Transplantation in Patients With Hematologic Malignancies Managed With Post-Transplant Cyclophosph...Charley Jang, Jingmei Hsu
Journal of Hematology. 2024-10-01 - 28 citationsEmergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections.Mohammed Nooruzzaman, Katherine E E Johnson, Ruchi Rani, Eli J Finkelsztein, Leonardo C Caserta
Nature Communications. 2024-09-18
Abstracts/Posters
- Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34+ pr...Jingmei Hsu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Haplo-Cord Transplantation with Anti-Thymocyte Globulin: Comparative Clinical Outcomes with or without Routine G-CSF AdministrationJingmei Hsu, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T Infusion61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Research Leaders Across New York State Form Empire State Cellular Therapy ConsortiumJuly 10th, 2025- First Woman to Receive Stem Cell Transplant for HIV Remains Virus-Free 5 Years LaterMarch 17th, 2023
- Another Person Cured of HIV Disease - but It Is a Special CaseMarch 17th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
